The company has not filed an annual or quarterly report since its Q3 FY2021 10-Q, filed Nov 12, 2021. Its latest SEC filing is a 15-12B from Nov 29, 2021.
10-Q for Q3 FY2021, filed Nov 12, 2021
The sections below describe the company as of the FY2020 annual report.
Markets ZILRETTA, an extended-release injection for knee osteoarthritis, to prescribing physicians and develops locally administered treatments for musculoskeletal conditions.
10-K for FY2020, filed Mar 10, 2021We are a biopharmaceutical company focused on the discovery, development and commercialization of novel, local therapies for the treatment…View ↗
ZILRETTA was approved by the U.S. Food & Drug Administration, or FDA, on October 6, 2017, and launched in the United States shortly…View ↗
We have a growing pipeline with two product candidates focused on the local treatment of musculoskeletal conditions: FX201 and FX301. FX201…View ↗
FX301, is a locally administered NaV1.7 inhibitor, known as funapide, formulated for extended release in a thermosensitive hydrogel. The…View ↗
Flexion sells ZILRETTA mainly to specialty distributors and a specialty pharmacy, with sales counted when each order is delivered to the customer.
10-K for FY2020, filed Mar 10, 2021
$85.6M
10-K for FY2020, filed Mar 10, 2021
$85.6M ↗
Flexion sells mainly through specialty distributors and a specialty pharmacy, which resell ZILRETTA to physicians, clinics, and some medical centers and hospitals. It also contracts directly with health care providers and purchasing groups.
10-K for FY2020, filed Mar 10, 2021Product Revenue, Net— The Company primarily sells ZILRETTA to specialty distributors and a specialty pharmacy, who then subsequently resell…View ↗
No. It lost $113.7M in FY2020.
10-K for FY2020, filed Mar 10, 2021
−$93MView ↗
10-K for FY2020, filed Mar 10, 2021
−$113.7MView ↗
10-K for FY2020, filed Mar 10, 2021
−$80.6MView ↗
10-Q for Q3 FY2021, filed Nov 12, 2021
−$30.3MView ↗
8-K, filed Nov 19, 2021
As previously disclosed, pursuant to the Merger Agreement, on October 22, 2021, Purchaser commenced a tender offer to acquire all of the…View ↗
8-K, filed Oct 12, 2021
TAMPA, FL and BURLINGTON, MA, October 11, 2021 – Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to…View ↗
8-K, filed May 12, 2021
The Company anticipates 2021 full-year ZILRETTA net sales in the range of $120 million to $130 million. In addition, total operating…View ↗
Pain focus expands
The older report described candidates for osteoarthritis; the latest also describes a locally administered nerve-block treatment for post-operative pain, alongside a gene therapy for osteoarthritis.
10-K for FY2017, filed Mar 8, 2018 10-K for FY2020, filed Mar 10, 2021Our pipeline includes FX101 and FX201. FX101 is a PLGA-based extended-release formulation of fluticasone, a well-established…View ↗
Competes with Ampio Pharmaceuticals, Anika Therapeutics, Centrexion Therapeutics, Eli Lilly, Kolon TissueGene, Pfizer, Regeneron Pharmaceuticals, Samumed, Taiwan Liposome, Teva Pharmaceutical Industries, and Xalud Therapeutics
10-K for FY2020, filed Mar 10, 2021Our industry is highly competitive and subject to rapid and significant technological change. The large size and expanding scope of the…View ↗
Loading...
